Diabetes, Heart and Cardiovascular Diseases News Chronicle.  Diabetes, Cardiovascular and Heart Diseases
 Article 291
    Published on January 18, 2018

Intensive blood pressure lowering treatment may not provide risk reduction to cardiovascular disease

A meta-analysis by the researchers at the Umea University, Sweden shows no reduction in death and cardiovascular disease risks with blood pressure lowering treatments among healthy people with systolic blood pressure below 140 mm Hg.

Systolic Blood Pressure Intervention Trial (SPRINT), a previous study done in 2015 has found a reduction in mortality and cardiovascular disease with a systolic blood pressure less than 120 mm Hg. But current study finding was opposite to SPRINT study finding and supports current guidelines.

Researchers have conducted a meta-analysis, which combines 74 randomized clinical trials conducted on more than 306,273 patients. The average age of the participants was 63.6 years and 39.9 percent of them were women participants. The analytical study found that the benefits of the reduction in systolic blood pressure of less than 140 mm Hg depends on its reading when an individual was healthy. There are no effects on mortality or cardiovascular events if the systolic blood pressure was below 140 mm Hg prior to first-ever cardiovascular events.

Researchers say treatments intended to lower blood pressure below 130 mm Hg is beneficial only to people with coronary heart disease. The treatment effect was neutral in primary prevention trials.

Intensive blood pressure lowering treatment may not reduce the risk of death and cardiovascular disease.

Lead author of the study was Dr. Mattias Brannstrom, MD, PhD, a researcher, the Department of Public Health and Clinical Medicine, Umea University, Sweden. The study findings were published October 1, 2017, in the JAMA Internal Medicine. Title of the article was "Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis." DOI : dx.doi.org/10.1001/jamainternmed.2017.6015

Facebook     GooglePlus     Twitter
If you like this article, please share it with a friend! Article address is (copy and paste the code below) :

Articles similar to this topic

1. American Heart Association guidelines say systolic reading of 130 mm Hg is the new high blood pressure reading
2. Cardiovascular disease, heart attack or stroke risks may be predicted and prevented by brain-scanning for the symptoms of stress and blood pressure
3. High-intensity interval training (HIIT) workout reduces the waist circumference, systolic blood pressure, insulin and blood sugar glucose levels
4. Risk for type 2 diabetes, high blood pressure and cardiovascular diseases with phthalate chemicals
6. Risk For High blood pressure Hypertension Being Short
7. Better Heart Health By Managing Blood Pressure And Sugar Levels
8. Should Blood Pressure Goals Differ In Patients With And Without Diabetes
9. Preventing Diabetes By Taking Blood Pressure Medication at Night
10. Risks With Blood Pressure And High Sugar Levels During Pregnancy



Reduction in arterial fat and reversal of atherosclerosis with the trodusquemine drug

A trodusquemine drug was effective in reducing weight (by stopping PTP1B enzyme) and inflammation, to suppress appetite, in improving insulin resistance associated with obesity and for the treatment of breast cancer. But a current study done by researchers at the University of Aberdeen, Scotland, shows a reduction in arterial fat and possible reversal of atherosclerosis (a risk factor for heart and cardiovascular CVD diseases) with a trodusquemine drug.

Preclinical studies with mice model show a trodusquemine drug has the ability to dissipate plaque and fat in the arteries. In some cases, just one dose is sufficient for the reversal of atherosclerosis. Study results show a decrease in the measured plaque formation, the complete reversal of atherosclerosis effects and prevention of risks associated with occlusion and thrombosis events.

The trodusquemine drug dosage of either once a week for five weeks or just once at the end of the study has resulted in a marked reduction in the atherosclerotic plaque area along with lower cholesterol and triglycerides.

The trodusquemine drug reduces cardiovascular diseases, arterial fat plaque and reverse atherosclerosis.

Authors of the study were Professor Mirela Delibegovic and Dr. Dawn Thompson from the University of Aberdeen's Institute of Medical Sciences, Aberdeen, Scotland. The study findings were published 29 September 2017, in the Clinical Science. Title of the article was "Pharmacological inhibition of protein tyrosine phosphatase 1B protects against atherosclerotic plaque formation in the LDLR-/- mouse model of atherosclerosis." DOI : doi.org/10.1042/CS20171066

Facebook     GooglePlus     Twitter
Post a message on social media and mail to your friend. Article address is (copy and paste the code below) :

Articles similar to this topic

1. Self-expanding (SE) stents outperform balloon-expandable (BE) stents for treating iliac artery (atherosclerosis) disease
2. DKK3 natural protein can protect against plaque formation, atherosclerosis, stroke and heart attack
3. AT04A vaccine reduces LDL cholesterol and atherosclerosis to prevent heart disease
4. About Atherosclerosis Disease
5. Skipping breakfast can cause atherosclerotic plaques, cardiovascular and heart diseases
6. Inflammation hormone risk with glucose-gobbling immune cells hidden in plaque of coronary artery disease CAD patients
7. Repatha Drug Reduces Plaque
8. Risk reduction to coronary heart or artery disease (CAD) and dementia by playing golf game


Occlusion : A clot blocking a blood vessel is known as vascular occlusion. The blockage may be partial or complete and leads to heart attack. This can be diagnosed with an ultrasound technique known as Doppler sonography.



Site maps

Site map 1   Site map 2   Site map 3   Site map 4

The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.

Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.